


AMENDMENTS TO THE CLAIMS


This Listing of the Claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A compound of formula I



wherein

R_a is H ; $C_{1-4}alkyl$; or $C_{1-4}alkyl$ substituted by OH , NH_2 , $NHC_{1-4}alkyl$ or $N(di-C_{1-4}alkyl)_2$; one of R_b , R_c , R_d and R_e is halogen; $C_{1-4}alkoxy$; or $C_{1-4}alkyl$; and the other three substituents are H ; or R_b , R_c , R_d and R_e are all H ; and R is a radical of formula (a)



(a)

wherein

R_1 is $-(CH_2)_n-NR_3R_4$, wherein

each of R_3 and R_4 , independently, is H or $C_{1-4}alkyl$; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R_2 is H ; halogen; $C_{1-4}alkyl$; CF_3 ; OH ; SH ; NH_2 ; NO_2 ; $C_{1-4}alkoxy$; $C_{1-4}alkylthio$; $NHC_{1-4}alkyl$; $N(di-C_{1-4}alkyl)_2$ or CN ;

or a salt thereof.

2. (Currently Amended) A compound according to claim 1 wherein R_a is H or methyl; one of R_b , R_c , R_d and R_e is methyl or ethyl and the other three substituents are H ; or R_b , R_c , R_d and R_e are all H ; R_2 is H ; Cl , methyl or NO_2 ; n is 1; and each of R_3 and R_4 , independently, is H , methyl, ethyl or *i*-propyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue, or a salt thereof.

3. (Original) A compound according to claim 1 or 2 which is selected from

3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;


3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;


3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; or a salt thereof.

4. (Original) A compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.
5. (Original) A pharmaceutical composition comprising a compound according to any one of claim 1 to 3, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.
6. (Original) Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treating or preventing diseases or disorders mediated by T lymphocytes and/or PKC.
7. (Original) Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection, cancer or infectious diseases.
8. (Original) A pharmaceutical combination comprising a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.
9. (Currently Amended) A process for the production of the compound of formula I according to claim 1 or claim 2, which process comprises reacting a compound of formula II



wherein R_a , R_b , R_c , R_d and R_e are as defined in claim 1 and claim 2,
with a compound of formula III



wherein R is as defined in claim 1 and claim 2,
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

10. (Original) A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to any one of claim 1 to 3, or a pharmaceutically acceptable salt thereof.